BMW Ventures Ltd
BMWBMW Ventures Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: profits are rising, but only 6% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a downtrend (23 weeks in) while the P/E sits at the 76th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +37.5% year on year, and 6% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
BMW Ventures Ltd trades at ₹56.3, in a downtrend and 23 weeks into that stage. That is −13.0% against its own 200-day average. It sits at 27% of a 52-week range of ₹51 to ₹70. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a downtrend — week 23 of stage 4, confirmed. At ₹56.3 it trades −13.0% versus its 200-day average and sits at 27% of its 52-week range (₹51–₹70).
Against the market, two honest reads. Cumulative: over the last 5 months the stock moved −20% while the NIFTY 500 moved −3% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-02-27) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
BMW Ventures Ltd trades at 12.2× P/E, at the pricey end of its own range (76th percentile). Its long-run median P/E is 11.5×, measured across 0.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 12.2× is at the pricey end of its own range (76th percentile), against a long-run median of 11.5× measured over 0.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
BMW Ventures Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +10.5% | +4.2% | +12.4% | — |
| Profit | +12.1% | +3.9% | +11.0% | — |
| EPS | −16.6% | −40.6% | −20.7% | — |
4-Factor Sector Score
50.0/100 — rank 16 of 49 in Trading · 55% evidence confidence
BMW Ventures Ltd scores 50.0 out of 100 against the 49 companies it is compared with in Trading, ranking 16. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 16.9 + 12 + 11.1 + 10 = 50. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
BMW Ventures Ltd reported ₹609 Cr of revenue in the Jun 26 quarter, +25.6% year on year. That is the 4th straight quarter of year-on-year growth. Over 6 years it has compounded at 12.3% a year. The last full year, FY26, came in at ₹2,278 Cr. The last four reported quarters add to ₹2,403 Cr.
FY26 revenue came in at ₹2,278 Cr (+10.5% on the year), capping 6 years at 12.3% compound. The latest quarter (Jun 26) printed ₹609 Cr, +25.6% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +18.1% growth against the decade's 12.3% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
BMW Ventures Ltd's operating margin is 3.4% in the Jun 26 quarter, −0.6 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 3.2% to 4.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 3.4%, −0.6 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 3.2%–4.0%.
🚨 Why the margin moved: operating margin went −0.6 pp year on year while gross margin went −1.5 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
BMW Ventures Ltd earned ₹11.0 Cr of net profit in the Jun 26 quarter, +37.5% year on year. Full-year FY26 profit was ₹37.0 Cr. The 6-year compound rate is 16.2%. That is 1.8% of the quarter's revenue. The same quarter a year earlier earned ₹8.0 Cr.
Jun 26 profit was ₹11.0 Cr, +37.5% year on year. On the full year, FY26 printed ₹37.0 Cr (+12.1%), and the 6-year compound rate is 16.2%.
Why profit moved: revenue contributed +25.6% and the margin −0.6 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +26.1% vs revenue +18.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 6% of BMW Ventures Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹8.0 Cr of operating cash against ₹37.0 Cr of profit. After ₹14.0 Cr of capital spending, ₹−6.0 Cr was left as free cash.
FY26: operating cash of ₹8.0 Cr against reported profit of ₹37.0 Cr, leaving free cash of ₹−6.0 Cr after ₹14.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 6% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 6%: the cash cycle stretched 28 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 28 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
BMW Ventures Ltd's cash conversion cycle runs 93 days in FY26, up from 65 days in FY21. Capital spending ran ₹65.0 Cr over the last 3 years. At FY26 sales of ₹2,278 Cr each day of that cycle holds about ₹6.2 Cr, so roughly ₹580 Cr sits inside the business at any moment.
FY26: debtors at 42 days, inventory at 53 days — roughly 1.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 93 days, looser than FY21's 65.
The full loop: cash goes out to suppliers and production on day 0; stock waits 53 days to sell; customers pay about 42 days after that; and suppliers themselves are paid at 1 days — netting out to the 93-day cycle.
In money terms: at FY26 sales of ₹2,278 Cr, each day of the cycle holds about ₹6.2 Cr — so the 93-day loop keeps roughly ₹580 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹65.0 Cr over the last 3 fiscal years against ₹15.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
BMW Ventures Ltd earns a ROCE of 12% in FY26. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 1.6% net margin on 3.03× asset turns.
FY26 ROCE is 12%.
Why the return is what it is — the wiring (FY26): 1.6% net margin × 3.03× asset turns × 1.70× balance-sheet leverage ≈ 8.2% on equity. Margin does its share; leverage is a meaningful part of the equation.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
BMW Ventures Ltd carries ₹258 Cr of borrowings against ₹442 Cr of equity in FY26, a debt-to-equity of 0.58. Operating profit covers the interest bill 3×. Over 5 years borrowings went from ₹173 Cr to ₹258 Cr. Capital spending ran ₹65.0 Cr across the last 3 of those years.
FY26: borrowings of ₹258 Cr against equity of ₹442 Cr — a debt-to-equity of 0.58. Operating profit covers the interest bill 3×. Over 5 years borrowings went from ₹173 Cr to ₹258 Cr while capital spending ran ₹65.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of BMW Ventures Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
BMW Ventures Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Onix Solar Energy LtdONIXSOLAR | 74.2/100Favorable setup69% evidence | 28.8/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence | 18.3/25 ROCE 32% · OPM 30% 76% evidence | 10.6/20 P/E 19.8× · PEG — 15% evidence | 16.5/20 RS sector 67.7% · RS bench 94.8% · 1Y 61.3%12 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 28.8 + 18.3 + 10.6 + 16.5 = 74.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Rashi Peripherals LtdRPTECH | 68.7/100Favorable setup75% evidence | LEADER | 24.5/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 14.7/25 ROCE 16.8% · OPM 3% 76% evidence | 10.7/20 P/E 17.4× · PEG — 15% evidence | 18.8/20 RS sector 57.1% · RS bench 82.2% · 1Y 197.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 14.7 + 10.7 + 18.8 = 68.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Magnus Steel & Infra Ltd517320 | 67.1/100Thin evidence · provisional56% evidence | 27.6/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.5/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 11.8/20 RS sector — · RS bench 46.1% · 1Y —4 of 5 weeks ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.6 + 18.5 + 9.2 + 11.8 = 67.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Nupur Recyclers LtdNRL | 67.0/100Favorable setup87% evidence | BREAKING OUT | 22.2/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence | 16.6/25 ROCE 15.1% · OPM 11.6% 95% evidence | 9.5/20 P/E 47.1× · PEG — 50% evidence | 18.7/20 RS sector 43.1% · RS bench 70.4% · 1Y 66.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 16.6 + 9.5 + 18.7 = 67 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shankara Buildpro LtdBUILDPRO | 63.1/100Mixed-positive evidence63% evidence | FADING | 25.3/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.4/25 ROCE 39% · OPM 3.2% 100% evidence | 10.4/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —7 of 12 weeks ahead 0% evidence |
| Exact sum: 25.3 + 17.4 + 10.4 + 10 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Mangalam Global Enterprise LtdMGEL | 61.0/100Mixed-positive evidence80% evidence | 25.3/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 16.1/25 ROCE 17% · OPM 1.9% 95% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 8.5/20 RS sector -18.9% · RS bench -0.2% · 1Y -9.8%10 of 11 weeks ahead 100% evidence | |
| Exact sum: 25.3 + 16.1 + 11.1 + 8.5 = 61 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Tembo Global Industries LtdTEMBO | 59.9/100Mixed-positive evidence80% evidence | TURNING | 21.8/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence | 18.5/25 ROCE 22.8% · OPM 16% 95% evidence | 11.3/20 P/E 11× · PEG — 15% evidence | 8.3/20 RS sector -17.6% · RS bench -0.1% · 1Y 27.5%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 18.5 + 11.3 + 8.3 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Euro Pratik Sales LtdEUROPRATIK | 59.7/100Mixed-positive evidence73% evidence | BREAKING OUT | 15.1/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence | 19.5/25 ROCE 38.4% · OPM 26% 100% evidence | 15.1/20 P/E 34.1× · PEG 0.62 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 10 weeks ahead 0% evidence |
| Exact sum: 15.1 + 19.5 + 15.1 + 10 = 59.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 9Ivalue Infosolutions LtdIVALUE | 59.6/100Mixed-positive evidence60% evidence | BREAKING OUT | 20.3/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 18.4/25 ROCE 25.4% · OPM 10% 95% evidence | 10.9/20 P/E 14.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 10 weeks ahead 0% evidence |
| Exact sum: 20.3 + 18.4 + 10.9 + 10 = 59.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Vision Infra Equipment Solutions LtdVIESL | 58.7/100Thin evidence · provisional56% evidence | FADING | 19.0/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.8/25 ROCE 22.6% · OPM 26% 95% evidence | 11.2/20 P/E 11.6× · PEG — 15% evidence | 8.7/20 RS sector -2.5% · RS bench 15.7% · 1Y 93%10 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 19.8 + 11.2 + 8.7 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Arisinfra Solutions LtdARIS | 57.8/100Mixed-positive evidence65% evidence | BASING | 21.7/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence | 15.3/25 ROCE 15.6% · OPM 11% 95% evidence | 10.8/20 P/E 16.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench 1.5% · 1Y -7.4%3 of 10 weeks ahead 25% evidence |
| Exact sum: 21.7 + 15.3 + 10.8 + 10 = 57.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Patel Retail LtdPATELRMART | 52.8/100Mixed-positive evidence60% evidence | FADING | 17.7/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence | 14.5/25 ROCE 15.3% · OPM 6.1% 95% evidence | 10.6/20 P/E 17.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -16.2%5 of 10 weeks ahead 0% evidence |
| Exact sum: 17.7 + 14.5 + 10.6 + 10 = 52.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Sudarshan Pharma Industries LtdSUDARSHAN | 51.1/100Mixed-positive evidence76% evidence | 20.5/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence | 13.7/25 ROCE 15.1% · OPM 9.1% 76% evidence | 11.3/20 P/E 35.6× · PEG — 50% evidence | 5.6/20 RS sector -23.8% · RS bench -7% · 1Y -15.7%2 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 20.5 + 13.7 + 11.3 + 5.6 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Fabtech Technologies LtdFABTECH | 50.8/100Thin evidence · provisional52% evidence | ASLEEP | 17.4/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.4/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.0/20 P/E 13.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 17.4 + 12.4 + 11 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Lloyds Enterprises LtdLLOYDSENT | 50.5/100Mixed-positive evidence75% evidence | FADING | 17.9/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence | 11.3/25 ROCE 3.7% · OPM 16% 76% evidence | 9.1/20 P/E 102× · PEG — 15% evidence | 12.2/20 RS sector -3.6% · RS bench 15.7% · 1Y -0.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 11.3 + 9.1 + 12.2 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16BMW Ventures Ltdthis pageBMW | 50.0/100Thin evidence · provisional55% evidence | 16.9/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence | 12.0/25 ROCE 12% · OPM 3.4% 76% evidence | 11.1/20 P/E 12.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.9 + 12 + 11.1 + 10 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Yogi LtdYOGI | 49.6/100Thin evidence · provisional58% evidence | 20.2/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence | 10.0/25 ROCE 12.8% · OPM 2.6% 76% evidence | 9.6/20 P/E 53.7× · PEG — 15% evidence | 9.8/20 RS sector -7% · RS bench 10.4% · 1Y -8.4%2 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 20.2 + 10 + 9.6 + 9.8 = 49.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18SG Mart LtdSGMART | 48.9/100Mixed-negative evidence90% evidence | LEADER | 14.1/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 95% evidence | 8.9/25 ROCE 10.2% · OPM 4.5% 95% evidence | 8.3/20 P/E 74.6× · PEG 1.92 65% evidence | 17.6/20 RS sector 31.8% · RS bench 54.6% · 1Y 125.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 8.9 + 8.3 + 17.6 = 48.9 · Decision use: Price leads the evidence: RS versus the benchmark is 54.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 19Shiv Aum Steels LtdSHIVAUM | 47.2/100Thin evidence · provisional55% evidence | TURNING | 16.8/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence | 11.4/25 ROCE 8% · OPM 4.7% 95% evidence | 7.6/20 P/E 64.1× · PEG — 50% evidence | 11.4/20 RS sector — · RS bench 34.1% · 1Y —2 of 2 weeks ahead 25% evidence |
| Exact sum: 16.8 + 11.4 + 7.6 + 11.4 = 47.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Adani Enterprises LtdADANIENT | 45.2/100Mixed-negative evidence93% evidence | LEADER | 14.5/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.5/25 ROCE 5.8% · OPM 15% 100% evidence | 7.7/20 P/E 173× · PEG 1.96 65% evidence | 14.5/20 RS sector 2.3% · RS bench 22% · 1Y 43.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 8.5 + 7.7 + 14.5 = 45.2 · Decision use: Price leads the evidence: RS versus the benchmark is 22%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21MMTC LtdMMTC | 45.0/100Mixed-negative evidence96% evidence | ASLEEP | 14.8/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence | 8.1/25 ROCE 8.7% · OPM — 84% evidence | 14.0/20 P/E 48× · PEG 0.92 100% evidence | 8.1/20 RS sector -18.2% · RS bench -1.3% · 1Y 1.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 8.1 + 14 + 8.1 = 45 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22State Trading Corporation of India LtdSTCINDIA | 42.8/100Thin evidence · provisional54% evidence | ASLEEP | 18.8/35 Revenue — · PAT 100% · OPM change -14.6 pp 43% evidence | 7.4/25 ROCE -0.9% · OPM — 60% evidence | 11.5/20 P/E 15.7× · PEG — 50% evidence | 5.1/20 RS sector -29.2% · RS bench -5.4% · 1Y -0.9%5 of 11 weeks ahead 70% evidence |
| Exact sum: 18.8 + 7.4 + 11.5 + 5.1 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Riddhi Siddhi Gluco Biols Ltd524480 | 42.4/100Mixed-negative evidence82% evidence | TURNING | 12.8/35 Revenue 74.8% · PAT 0% · OPM change -2.8 pp 95% evidence | 6.5/25 ROCE 2.7% · OPM -3% 76% evidence | 6.6/20 P/E 38.6× · PEG — 50% evidence | 16.5/20 RS sector 8.6% · RS bench 29% · 1Y 42.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 6.5 + 6.6 + 16.5 = 42.4 · Decision use: Price leads the evidence: RS versus the benchmark is 29%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 24RRP Semiconductor LtdRRP | 41.7/100Thin evidence · provisional54% evidence | 11.4/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence | 5.5/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.8/20 RS sector 64.7% · RS bench 6.5% · 1Y 142.7%0 of 1 week ahead 70% evidence | |
| Exact sum: 11.4 + 5.5 + 10 + 14.8 = 41.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Cropster Agro Ltd523105 | 40.5/100Mixed-negative evidence65% evidence | 15.9/35 Revenue 28.4% · PAT 6.5% · OPM change 2.1 pp 83% evidence | 11.3/25 ROCE 12.4% · OPM 8.7% 76% evidence | 10.3/20 P/E 31× · PEG — 15% evidence | 3.0/20 RS sector -72.9% · RS bench -62.7% · 1Y -70.2%0 of 4 weeks ahead 70% evidence | |
| Exact sum: 15.9 + 11.3 + 10.3 + 3 = 40.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Dhunseri Ventures LtdDVL | 40.3/100Mixed-negative evidence87% evidence | TURNING | 12.6/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence | 9.7/25 ROCE 6.7% · OPM 39% 95% evidence | 9.2/20 P/E 4.9× · PEG — 50% evidence | 8.8/20 RS sector -21.7% · RS bench -4.2% · 1Y -22.4%4 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 9.7 + 9.2 + 8.8 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Hardwyn India LtdHARDWYN | 39.7/100Mixed-negative evidence87% evidence | ASLEEP | 13.7/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence | 12.4/25 ROCE 4.8% · OPM 13% 95% evidence | 11.7/20 P/E 62.6× · PEG — 50% evidence | 1.9/20 RS sector -28.8% · RS bench -15.6% · 1Y 23.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.7 + 12.4 + 11.7 + 1.9 = 39.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Blue Pearl Agriventures LtdBPAGRI | 39.5/100Mixed-negative evidence69% evidence | 20.3/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence | 6.3/25 ROCE 2.2% · OPM 3.3% 76% evidence | 8.7/20 P/E 514× · PEG — 15% evidence | 4.2/20 RS sector -33.9% · RS bench -25.1% · 1Y -48.7%1 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 20.3 + 6.3 + 8.7 + 4.2 = 39.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29PTC India LtdPTC | 39.4/100Mixed-negative evidence82% evidence | ASLEEP | 13.4/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.7/25 ROCE 13.4% · OPM 3.1% 76% evidence | 10.6/20 P/E 9.3× · PEG — 50% evidence | 2.7/20 RS sector -24.1% · RS bench -8.7% · 1Y -7.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 13.4 + 12.7 + 10.6 + 2.7 = 39.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Hexa Tradex LtdHEXATRADEX | 38.8/100Mixed-negative evidence65% evidence | ASLEEP | 16.9/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence | 6.2/25 ROCE -0.1% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.7/20 RS sector -23.2% · RS bench -6.9% · 1Y -12.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 6.2 + 10 + 5.7 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Neueon Corporation LtdNEUEON | 38.0/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence | 3.8/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.1/20 RS sector 12.7% · RS bench 44.5% · 1Y —5 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.8 + 10 + 15.1 = 38 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Kothari Industrial Corporation LtdKOTIC | 33.8/100Adverse evidence63% evidence | ASLEEP | 18.7/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence | 1.6/25 ROCE -28.9% · OPM -43% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -58.8% · RS bench -47.8% · 1Y -68.7%0 of 7 weeks ahead 70% evidence |
| Exact sum: 18.7 + 1.6 + 10 + 3.5 = 33.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33BN Agrochem LtdBNAGROCHEM | 32.8/100Adverse evidence77% evidence | ASLEEP | 12.7/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence | 4.4/25 ROCE 4.4% · OPM 2.3% 100% evidence | 9.1/20 P/E 140× · PEG — 15% evidence | 6.6/20 RS sector -17.1% · RS bench -23.3% · 1Y -22.5%6 of 8 weeks ahead 70% evidence |
| Exact sum: 12.7 + 4.4 + 9.1 + 6.6 = 32.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34Shanti Overseas (India) LtdSHANTI | 32.3/100Thin evidence · provisional56% evidence | 11.2/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.6/25 ROCE -25.2% · OPM -216.5% 71% evidence | 13.2/20 P/E 3× · PEG — 50% evidence | 3.3/20 RS sector -60.6% · RS bench -49.7% · 1Y -51.6%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.2 + 4.6 + 13.2 + 3.3 = 32.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 35Uniphos Enterprises LtdUNIENTER | 30.1/100Adverse evidence69% evidence | ASLEEP | 12.4/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence | 4.6/25 ROCE 0.8% · OPM — 80% evidence | 9.0/20 P/E 32.7× · PEG — 50% evidence | 4.1/20 RS sector -43.9% · RS bench -24.1% · 1Y -38%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 4.6 + 9 + 4.1 = 30.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Oswal Agro Mills LtdOSWALAGRO | 24.3/100Adverse evidence67% evidence | ASLEEP | 2.7/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.8/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.8/20 RS sector -50.6% · RS bench -32% · 1Y -50.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 2.7 + 7.8 + 10 + 3.8 = 24.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Bizotic Commercial LtdBIZOTIC | 64.9/100Thin evidence · provisional45% evidence | 19.8/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 18.6/25 ROCE 26.8% · OPM 8% 76% evidence | 9.7/20 P/E 48.7× · PEG — 15% evidence | 16.8/20 RS sector 89.2% · RS bench 102% · 1Y 262%10 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 19.8 + 18.6 + 9.7 + 16.8 = 64.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38Proventus Agrocom LtdPROV | 57.0/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.6/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.5/25 ROCE 11.5% · OPM 1.8% 95% evidence | 13.3/20 P/E 45.4× · PEG — 50% evidence | 11.6/20 RS sector — · RS bench 39.7% · 1Y —8 of 8 weeks ahead 25% evidence |
| Exact sum: 19.6 + 12.5 + 13.3 + 11.6 = 57 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 39Mardia Samyoung Capillary Tubes Company LtdMSCTC | 56.6/100Thin evidence · provisional32% evidence | 20.8/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.2/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.6/20 P/E 687× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 74.6% · 1Y 176.1%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.8 + 15.2 + 8.6 + 12 = 56.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 40SK Minerals & Additives Ltd544584 | 55.9/100Thin evidence · provisional36% evidence | 16.6/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 18.9/25 ROCE 26.2% · OPM 10.7% 76% evidence | 10.4/20 P/E 25.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 16.6 + 18.9 + 10.4 + 10 = 55.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 41Aayush Art and Bullion LtdAAYUSHBULL | 55.4/100Thin evidence · provisional48% evidence | 21.1/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.2/25 ROCE 18.9% · OPM 6% 76% evidence | 8.9/20 P/E 243× · PEG — 15% evidence | 12.2/20 RS sector 0.1% · RS bench 18.5% · 1Y 20.6%10 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 21.1 + 13.2 + 8.9 + 12.2 = 55.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Monika Alcobev LtdMONIKA | 53.9/100Thin evidence · provisional22% evidence | 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.0/25 ROCE 21% · OPM 15% 57% evidence | 10.5/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -11.2%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.4 + 17 + 10.5 + 10 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Shah Foods Ltd519031 | 53.6/100Thin evidence · provisional18% evidence | 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence | 15.3/25 ROCE — · OPM 18% 30% evidence | 8.9/20 P/E 248× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 96.2% · 1Y — 25% evidence | |
| Exact sum: 17.1 + 15.3 + 8.9 + 12.3 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44Pramara Promotions LtdPRAMARA | 51.9/100Thin evidence · provisional47% evidence | 16.6/35 Revenue — · PAT — · OPM change -1 pp 15% evidence | 14.1/25 ROCE 15.2% · OPM 15% 71% evidence | 6.9/20 P/E 51.3× · PEG — 50% evidence | 14.3/20 RS sector 5.7% · RS bench 29% · 1Y 58.3%10 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 16.6 + 14.1 + 6.9 + 14.3 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Manbro Industries Ltd512595 | 51.3/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.1/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.9/20 RS sector -17.3% · RS bench 37.2% · 1Y 40.1%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.1 + 10 + 9.9 = 51.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46Satani Bearings LtdSATANIBRG | 46.0/100Thin evidence · provisional38% evidence | 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence | 4.5/25 ROCE 1% · OPM -3.7% 76% evidence | 8.6/20 P/E 5055× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 116.9% · 1Y 189.8%10 of 10 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.5 + 4.5 + 8.6 + 12.4 = 46 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Le Merite Exports LtdLEMERITE | 45.9/100Thin evidence · provisional46% evidence | 18.9/35 Revenue — · PAT — · OPM change 0.9 pp 15% evidence | 9.1/25 ROCE 8.6% · OPM 2.8% 71% evidence | 9.3/20 P/E 87× · PEG — 15% evidence | 8.6/20 RS sector -12.1% · RS bench 15% · 1Y 45.9%2 of 12 weeks ahead to 2026-05-17 100% evidence | |
| Exact sum: 18.9 + 9.1 + 9.3 + 8.6 = 45.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48Keto Motors Ltd537392 | 43.1/100Thin evidence · provisional38% evidence | 16.1/35 Revenue — · PAT -41.7% · OPM change — 33% evidence | 6.0/25 ROCE -0.3% · OPM 10.7% 76% evidence | 8.5/20 P/E 6428× · PEG — 15% evidence | 12.5/20 RS sector — · RS bench 341.9% · 1Y — 25% evidence | |
| Exact sum: 16.1 + 6 + 8.5 + 12.5 = 43.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49A-1 LtdA1L | 40.8/100Thin evidence · provisional50% evidence | 16.2/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 10.8/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.8/20 P/E 383× · PEG — 15% evidence | 5.0/20 RS sector -24.9% · RS bench -16% · 1Y 25.3%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.2 + 10.8 + 8.8 + 5 = 40.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is BMW Ventures Ltd's share price today?
BMW Ventures Ltd trades at ₹56.3. The company is valued at ₹489 Cr. The stock sits at 27% of its 52-week range of ₹51–₹70, −13.0% versus its 200-day average. On the tape, the price is in a downtrend, 23 weeks in. — as of 18 August 2026.
What were BMW Ventures Ltd's latest quarterly results?
BMW Ventures Ltd reported revenue of ₹609 Cr and net profit of ₹11.0 Cr for the Jun 26 quarter. Revenue rose 25.6% and profit rose 37.5% year on year. Earnings per share were ₹1.22. The operating margin was 3.4%, 0.6 pp lower than a year earlier. — as of 18 August 2026.
What is BMW Ventures Ltd's revenue?
BMW Ventures Ltd reported revenue of ₹609 Cr in the Jun 26 quarter, +25.6% year on year. For the full FY26 fiscal year, revenue was ₹2,278 Cr (+10.5%). Over the last 6 years revenue compounded at 12.3% a year. — as of 18 August 2026.
What is BMW Ventures Ltd's profit?
BMW Ventures Ltd earned ₹11.0 Cr of net profit in the Jun 26 quarter, +37.5% year on year. Full-year FY26 profit was ₹37.0 Cr. The operating margin ran 3.4% in the latest quarter. — as of 18 August 2026.
What is BMW Ventures Ltd's market cap?
BMW Ventures Ltd's market capitalisation is ₹489 Cr at a share price of ₹56.3. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 18 August 2026.
What is BMW Ventures Ltd's P/E ratio?
BMW Ventures Ltd trades at a P/E of 12.2×, at the 76th percentile of its own 1-year range, against a long-run median of 11.5×. This is a comparison with the stock's own history, not a value call — as of 18 August 2026.
Does BMW Ventures Ltd pay a dividend?
Yes — BMW Ventures Ltd's dividend payout was 35% of profit in FY26, and it recorded a payout in 2 of its last 7 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 18 August 2026.
Is BMW Ventures Ltd overvalued?
On its own history, BMW Ventures Ltd looks expensive: its P/E of 12.2× sits at the 76th percentile of its 1-year range (long-run median 11.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 18 August 2026.
Is BMW Ventures Ltd growing?
Yes — BMW Ventures Ltd is growing: latest-quarter revenue +25.6% year on year, profit +37.5%, and the margin −0.6 pp at 3.4%. The 6-year compound rates are 12.3% (revenue) and 16.2% (profit). The earnings engine currently reads: improving — as of 18 August 2026.
How is BMW Ventures Ltd performing?
BMW Ventures Ltd is in a downtrend, 23 weeks in. Its latest quarter's revenue rose 25.6% and profit rose 37.5% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 18 August 2026.
Is BMW Ventures Ltd in an uptrend?
No — the price is in a downtrend (week 23 of stage 4), trading −13.0% versus its 200-day average and at 27% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 18 August 2026.
Is BMW Ventures Ltd beating the market?
Not lately — on a trailing-13-week view BMW Ventures Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-02-27), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5 months the stock moved −20% against the NIFTY 500's −3% — behind the index over the full window. — as of 18 August 2026.
Will BMW Ventures Ltd's share price go up?
This page publishes no price forecast for BMW Ventures Ltd. What it measures instead: the share price is ₹56.3, the price is in a downtrend 23 weeks in. Its P/E of 12.2× sits at the 76th percentile of its own 1-year range. — as of 18 August 2026.
Who owns BMW Ventures Ltd?
Promoters hold 73.0% of BMW Ventures Ltd, foreign institutions 0.0%, domestic institutions 1.2% and the public 25.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 18 August 2026.
Does BMW Ventures Ltd have too much debt?
It is moderate — BMW Ventures Ltd's debt-to-equity is 0.58, and operating profit covers the interest bill 3×. FY26 borrowings were ₹258 Cr against equity of ₹442 Cr. Read the returns on this page with that leverage in mind — as of 18 August 2026.
What is BMW Ventures Ltd's capex?
BMW Ventures Ltd spent ₹65.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹14.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 18 August 2026.
What is BMW Ventures Ltd's cash flow?
BMW Ventures Ltd generated ₹8.0 Cr of operating cash flow in FY26 and ₹−6.0 Cr of free cash flow after ₹14.0 Cr of capital spending. Reported profit that year was ₹37.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 18 August 2026.
Is BMW Ventures Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 6% of BMW Ventures Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹8.0 Cr against reported profit of ₹37.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 18 August 2026.
Where is BMW Ventures Ltd in its business cycle?
BMW Ventures Ltd's FY26 operating margin was 3.6%, against a 7-year band of 3.2%–4.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 3.4%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 18 August 2026.
What could break the BMW Ventures Ltd story?
The sharpest disagreement: profits are rising, but only 6% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 18 August 2026.
Is BMW Ventures Ltd a stock worth studying right now?
This is not investment advice. The machine read: BMW Ventures Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 18 August 2026.